Most recently reported pay: $4.6M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
Nov 3, 2026https://www.cnbc.com/2026/11/03/genmab-cancer-drugs-petosemtamab.htmlsentiment +0.40
Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.
Nov 2, 2026https://247wallst.com/investing/2026/11/02/eli-lilly-jumped-6-after-earnings-its-up-68-in-a-year-where-does-the-target-go-now/sentiment -0.20
Nasdaq closes 1.38% lower on AI spending and inflation concerns
Oct 29, 2026https://invezz.com/news/2026/10/29/nasdaq-closes-1-38-lower-on-ai-spending-and-inflation-concerns/sentiment +0.60
PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade)
Oct 29, 2026https://seekingalpha.com/article/4959052-pph-key-pharmaceutical-innovations-support-bullish-outlook-upgradesentiment +0.60
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial
Oct 24, 2026https://www.marketbeat.com/instant-alerts/event-moderna-melanoma-therapy-cuts-recurrence-risk-42-in-phase-3-trial-2026-10-24/sentiment +0.50
Biotech stocks are surging. How investors can play the new drug innovation boom
Oct 24, 2026https://www.cnbc.com/2026/10/24/biotech-stocks-drug-innovation-rally.htmlsentiment +0.70
